BMP7 and breast carcinoma: Bone morphogenetic protein 7 (BMP7), a TGF-β-induced EMT antagonist [53], was a positive regulator of mesenchymal–epithelial transition (MET, the reverse of EMT) and was significantly decreased in mice of chronic renal injury [54], which was demonstrated in prostate and breast cancer cells too [55, 56].